135 results on '"Monif, Mastura"'
Search Results
2. P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma
3. MicroRNAs in adult high-grade gliomas: Mechanisms of chemotherapeutic resistance and their clinical relevance
4. Cognitive and psychopathological outcomes in acute disseminated encephalomyelitis
5. Failure of alemtuzumab therapy in three patients with MOG antibody associated disease
6. Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic
7. Clinical outcomes among initial survivors of cryptogenic new‐onset refractory status epilepsy (NORSE)
8. Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer
9. Clinical outcomes among initial survivors of cryptogenic new-onset refractory status epilepsy (NORSE)
10. Inflammatory complications of CGRP monoclonal antibodies: a case series
11. P2X7 receptor antagonism inhibits tumour growth in human high-grade gliomas
12. Development and Validation of a Peripheral Cell Ratio and Lactate Score for Differentiating Status Epilepticus from Prolonged Psychogenic Non‐Epileptic Seizures
13. Inhibition of purinergic P2X receptor 7 (P2X7R) decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) expression in U251 glioblastoma cells
14. Movement disorders in cell surface antibody mediated autoimmune encephalitis: a meta-analysis
15. The NLRP3 inflammasome in traumatic brain injury: potential as a biomarker and therapeutic target
16. Development and validation of a peripheral cell ratio and lactate score for differentiating status epilepticus from prolonged psychogenic nonepileptic seizures.
17. Nogo receptor-Fc delivered by haematopoietic cells enhances neurorepair in a multiple sclerosis model
18. Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
19. Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active relapsing-remitting multiple sclerosis
20. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation
21. Nogo receptor-Fc delivered by haematopoietic cells enhances neurorepair in a multiple sclerosis model.
22. Effectiveness of Bioinks and the Clinical Value of 3D Bioprinted Glioblastoma Models: A Systematic Review
23. Autoimmune Encephalitis in Long-Standing Schizophrenia: A Case Report
24. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
25. Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)
26. Editorial: Interactions of the Nervous System With Bacteria
27. Elevated Serum Interleukin-1β Levels in Male, but not Female, Collision Sport Athletes with a Concussion History
28. Efficacy of Cladribine Tablets as a Treatment for People with Multiple Sclerosis : Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-Term Efficacy and Biomarker Australian Study)
29. Cerebellar Ataxia Followed by Stiff Person Syndrome in a Patient with Anti-GAD Antibodies
30. The prevalence of epileptic seizures in multiple sclerosis in a large tertiary hospital in Australia
31. Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic Disorders
32. Inflammation, ictogenesis, and epileptogenesis: An exploration through human disease
33. Genetic prion disease: D178N with 129MV disease modifying polymorphism—a clinical phenotype
34. Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis
35. Seizures in autoimmune encephalitis: Kindling the fire
36. Vitamin D status in an Australian patient population: a large retrospective case series focusing on factors associated with variations in serum 25(OH)D
37. A Simple and Reliable Protocol for the Preparation and Culturing of Fresh Surgically Resected Human Glioblastoma Tissue
38. Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic Disorders.
39. Innate Immunity in the Central Nervous System: A Missing Piece of the Autoimmune Encephalitis Puzzle?
40. Prognosis in autoimmune encephalitis: Database
41. Inflammation, ictogenesis, and epileptogenesis: An exploration through human disease.
42. Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis
43. Peripheral Immune Cell Ratios and Clinical Outcomes in Seropositive Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium.
44. The NLRP3 inflammasome in traumatic brain injury: potential as a biomarker and therapeutic target.
45. Vitamin D status in an Australian patient population: a large retrospective case series focusing on factors associated with variations in serum 25(OH)D.
46. MonoMac syndrome with associated neurological deficits and longitudinally extensive cord lesion
47. Interleukin-1β has trophic effects in microglia and its release is mediated by P2X7R pore
48. P2X7 receptors are a potential novel target for anti-glioma therapies
49. P2X7 receptors are a potential novel target for antiglioma therapies.
50. The P2X7 Receptor Drives Microglial Activation and Proliferation: A Trophic Role for P2X7R Pore.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.